androsterone has been researched along with Premenstrual Dysphoric Disorder in 1 studies
Premenstrual Dysphoric Disorder: A condition in which a woman suffers from severe depression, irritability, and tension before MENSTRUATION. Premenstrual dysphoric disorder (PMDD) may involve a wide range of physical or emotional symptoms, which are more severe and debilitating than those seen with premenstrual syndrome (PMS), and which include at least one mood-related symptom. Symptoms usually stop when, or shortly after, menstruation begins.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To test this hypothesis, we stabilized neurosteroid levels by administering the 5α-reductase inhibitor dutasteride to block conversion of progesterone to its neurosteroid metabolite allopregnanolone in women with premenstrual dysphoric disorder (PMDD) and in asymptomatic control women." | 9.22 | 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. ( Cintron, D; Khine, KK; Koziol, DE; Martinez, PE; Morrow, AL; Nieman, LK; Rubinow, DR; Schiller, CE; Schmidt, PJ; Thompson, KD, 2016) |
| " To test this hypothesis, we stabilized neurosteroid levels by administering the 5α-reductase inhibitor dutasteride to block conversion of progesterone to its neurosteroid metabolite allopregnanolone in women with premenstrual dysphoric disorder (PMDD) and in asymptomatic control women." | 5.22 | 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. ( Cintron, D; Khine, KK; Koziol, DE; Martinez, PE; Morrow, AL; Nieman, LK; Rubinow, DR; Schiller, CE; Schmidt, PJ; Thompson, KD, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez, PE | 1 |
| Rubinow, DR | 1 |
| Nieman, LK | 1 |
| Koziol, DE | 1 |
| Morrow, AL | 1 |
| Schiller, CE | 1 |
| Cintron, D | 1 |
| Thompson, KD | 1 |
| Khine, KK | 1 |
| Schmidt, PJ | 1 |
1 trial available for androsterone and Premenstrual Dysphoric Disorder
| Article | Year |
|---|---|
5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.
Topics: 5-alpha Reductase Inhibitors; Adult; Androsterone; Cholestenone 5 alpha-Reductase; Double-Blind Meth | 2016 |